NovoSeven Use In Pregnancy & Lactation

factor viia, recombinant


Novo Nordisk


Full Prescribing Info
Use In Pregnancy & Lactation
Pregnancy: As a precautionary measure, it is preferable to avoid the use of NovoSeven during pregnancy. Data on a limited number of exposed pregnancies within approved indications indicate no adverse effects of rFVIIa on pregnancy or on the health of the foetus/newborn child. To date, no other relevant epidemiological data are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Breastfeeding: It is unknown whether rFVIIa is excreted in human breast milk. The excretion of rFVIIa in milk has not been studied in animals. A decision on whether to continue/discontinue breastfeeding or to continue/discontinue therapy with NovoSeven should be made taking into account the benefit of breastfeeding to the child and the benefit of NovoSeven therapy to the woman.
Fertility: Data from non-clinical studies as well as post-marketing data show no indication that rFVIIa has a harmful effect on male or female fertility.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in